Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2011-10-09 Capital/Financing Update
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
HEPATITIS C PHASE 2A TRIAL POSITIVE RESULTS 3 pages 168.5KB
Capital/Financing Update Classification · 95% confidence The document is a press release dated 10 October 2011 from Biotron Limited announcing positive results from a Phase 2a clinical trial of their drug BIT225 for Hepatitis C. It contains detailed information about the trial design, patient outcomes, and future plans for the drug development. The content focuses on clinical trial results and scientific data rather than financial results or regulatory filings. It is not an earnings release, annual report, or any regulatory filing. It is a capital markets announcement about clinical trial progress and drug development milestones, which fits best under Capital/Financing Update (CAP) as it informs investors about significant progress in the company's drug pipeline that could impact valuation and financing.
2011-10-09 English
Trading Halt 2 pages 62.7KB
Regulatory Filings Classification · 95% confidence The document is a market release dated 7 October 2011 from Biotron Limited requesting a trading halt on its securities pending the release of an announcement related to preliminary results from a Phase IIa hepatitis C clinical trial. The text is short (1798 characters) and primarily serves as a formal request for a trading halt, not the release of financial results or a report itself. There is no financial data, no detailed report, or analysis included. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement related to trading status and compliance with listing rules, rather than a financial report or announcement of voting results, management changes, or capital updates.
2011-10-06 English
Landmark HIV Trial Underway 2 pages 25.7KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 29 September 2011 from Biotron Limited regarding the commencement of a phase 1b/2a clinical trial for their HIV drug candidate BIT225. It describes the trial design, the drug's mechanism, and expected completion date. The document is short (3586 characters), does not contain financial data, regulatory form references, or detailed financial results. It is an update on a clinical trial milestone rather than a financial report or regulatory filing. It is not an earnings release, annual report, or management discussion. It is a general regulatory announcement about a clinical trial progress, suitable for classification as a Regulatory Filing (RNS).
2011-09-28 English
Year End Accounts and Preliminary Final Report 50 pages 263.4KB
Annual Report Classification · 100% confidence The document is titled 'YEAR END ACCOUNTS AND PRELIMINARY FINAL REPORT' and includes an Appendix 4E Preliminary Final Report for the year ended 30 June 2011. It references the attached Annual Report which forms part of this Preliminary Final Report. The document contains detailed financial statements, operating and financial review, directors' report, auditor's report, and other comprehensive financial information typical of an Annual Report. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, this document is the full Annual Report for the fiscal year ending 30 June 2011. FY 2011
2011-08-29 English
Letter to Shareholders 3 pages 221.6KB
Regulatory Filings Classification · 95% confidence The document is a shareholder update letter dated 29 July 2011 from Biotron Limited. It discusses progress on clinical trials, upcoming data releases, and general company updates. It is addressed to shareholders and mentions compliance with Listing Rule 3.17, indicating it is a regulatory announcement to shareholders. The document does not contain financial statements, detailed financial analysis, or comprehensive management discussion typical of annual or interim reports. It is not a transcript, audit report, or capital update. The document is a communication to shareholders providing operational updates and trial progress, which fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and shareholder update that does not fit other specific categories. The document length (6038 characters) and content confirm it is not merely a report publication announcement but a substantive update. Therefore, the best classification is Regulatory Filings (RNS).
2011-07-28 English
Appendix 4C - quarterly 5 pages 52.6KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed quarterly financial data including consolidated cash flow statements, payments to directors, financing facilities, reconciliation of cash, and compliance statements. The presence of quarterly financial data and the nature of the report align with a comprehensive interim or quarterly financial report. The document length is 7065 characters, which is sufficient to contain substantive financial data rather than just an announcement or certification. The document is not an annual report, audit report, earnings release, or any other category but fits best as an Interim / Quarterly Report (IR). Q4 2011
2011-07-26 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.